Eye Surgeon
iDoctor
Innovator
Prof. Ianchulev is an inventor and innovator who has pioneered sight-saving treatments used in millions of patients worldwide.
Entreprenuer
Humanitarian
Pioneering Innovations
Known as one of the most prolific ophthalmic inventors and entrepreneurs, Dr. Ianchulev has been at the forefront of ophthalmic innovation with many FDA-approved medical products. His technologies have transformed the ophthalmic field and are impacting eye care around the globe.
Ora
Dr. Ianchulev invented intraoperative aberrometry - the first intra-operative biometry device for surgical intervention in ophthalmology. The ORA system uses infrared laser aberrometry for high-precision cataract surgery. It has been used in more than 3 million cataract surgeries worldwide.
miLOOP
Dr. Ianchulev is the inventor of the miLOOP and founder of Iantech, Inc. miLOOP® is a memory-shaped, super-elastic nitinol fragmentation device for micro-interventional cataract surgery.
Optejet
Dr. Ianchulev led the development of the first FDA-approved pipette-free topical ophthalmic delivery system as well as the first smart, micro-dosing and horizontal-delivery technology in eye care.
miCOR
Dr. Ianchulev founded Iantech Inc. in 2014 to create a first-in-class micro-interventional platform for subsonic, cavitation-free lensectomy and cataract surgery.
TREX
Dr. Ianchulev is the founder of Iantrek, Inc. and the inventor of the T-Rex gonio-interventional technology for glaucoma surgery, which received FDA approval in 2021.
Cyclopen
Dr. Ianchulev is the founder of Iantrek, Inc. and the inventor of the CycloPen supraciliary micro-interventional technology for glaucoma surgery, which received FDA approval in 2021.
Macustat: Peristat
More than 20 years ago, Dr. Ianchulev developed the first 100% virtual diagnostic devices (Peristat, Macustat) in eye care for remote vision testing and diagnosis of retinal and optic nerve diseases.
RemoniHealth
Dr. Ianchulev co-founded RemoniHealth, Inc - the first vision-as-aservice (VaaS) platform for remote patient monitoring and remote care management.
AlloStent
The AlloStent is the first bio-stent made entirely of biological material with no implantable hardware. It is used in the interventional treatment of glaucoma.
CyPASS
The first suprachoroidal MIGS stent to receive FDA approval. Used in thousands of patients worldwide.
Preceyes
Dr. Ianchulev's team at New York Eye and Ear and their work with Preceyes, Inc. led to the introduction of micro-interventional robotics in ophthalmic surgery by Zeiss Meditec. ophthalmic surgery (Zeiss Meditec).
LUCENTIS
While at Genentech, Dr. Ianchulev lead the clinical research for Lucentis and the initial clinical efforts for one of the first bi-specific antibodies Vabyssmo.
Propionic Aciduria Optic Neuropathy
In 2002, Dr. Ianchulev was the first to describe the syndrome of propionic acuduria and optic neuropathy in children.
Office based cataract surgery
With his seminal population health research on office based eye surgery and his 2016 publication of 21,000 cases, Dr. Ianchulev pioneered a new surgical paradigm with tremendous efficiency and cost-savings.
Eye Surgeon
Dr. Ianchulev is a pioneering inventor in the field of eye surgery, responsible for groundbreaking surgical technologies.
Background
Dr. Ianchulev received both his medical degree (MD) and a Master of Public Health (MPH) degree from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. He is currently a Professor of Ophthalmology at New York Eye and Ear of Mount Sinai where he also directs the program for technology and innovation.
Procedures
Dr. Ianchulev has successfully performed over 4,000 eye surgeries, improving the quality of life for his patients.
Preceyes
Dr. Ianchulev's team at New York Eye and Ear and their work with Preceyes, Inc. led to the introduction of micro-interventional robotics in ophthalmic surgery by Zeiss Meditec. ophthalmic surgery (Zeiss Meditec).
Academic Leadership and Research
As a Professor of Ophthalmology, Dr. Ianchulev is recognized for his accomplishments and work in teaching and research. He has trained and held appointments at top academic institutions: Harvard Medical School, Harvard School of Public Health, University of California San Francisco (UCSF), Doheny Eye Institute (UCLA), and New York Eye and Ear Hospital (NYEE). His innovative research has led to patents, licenses, and commercial products and has been cited by more than 4,000 peer-reviewed publications. He was an invited expert by the US Congress on matters of medical innovation and FDA regulation.
Media and Presentations
Dr. Ianchulev is an invited speaker at national and international conferences. His expertise is sought by industry, academia and even Congress on matters of eye care, medical innovation, and public health. Dr. Ianchulev sits on the Board of multiple companies and foundations.
2024 Keynote Address Glaucoma 360
2011 Congressional Hearing
AAO Robotics Presentation
Glaucoma 360 Presentation
Innovation Design Gallery
A select compilation of Dr. Ianchulev’s technology artwork, designs, and campaign ads
See more
Additional Media
Media coverage of Dr. Ianchulev's seminal works.
NYEE 2024 Specialty Report
Top Innovators Delve into Latest Concepts at G360's New Horizon forum
New Supraciliary Interventions for Glaucoma : Increased attention is being given to this anatomic space for glaucoma procedures.
Dr. Ianchulev Keynote Speaker at the Glaucoma 360 New Horizon Forum 2024
The impatient innovator: Dr. Ianchulev
The Steve Jobs of Ophthalmology
Health Tech: Dr. Sean Ianchulev Of Eyenovia On How Their Technology Can Make An Important Impact On Our Overall Wellness
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
Robotics in Ophthalmology: The future of surgery is likely human and robotic collaboration
Robot-Assisted Glaucoma Surgery: Reaching new levels of precision in surgical glaucoma care with a first-in-class robotic system.
AAO 2023: Suprachoroidal outflow enhancement without implantable hardware: surgical technique and clinical results of a novel supraciliary MIGS
Congressional hearing on the impact of medical device regulation: Dr. Chang speaks with Dr. Ianchulev
Small drop delivers big advancement
Micro-dosing of phenylephrine comparable to conventional dropper administration
Ahead of the curve: NYEE Ophthalmic Innovation and Technology Program Head Dr. Ianchulev introduces surgical robotics on the 200th anniversary of NYEE